{"id":59410,"date":"2026-03-13T21:43:14","date_gmt":"2026-03-13T13:43:14","guid":{"rendered":"https:\/\/flcube.com\/?p=59410"},"modified":"2026-03-13T21:43:15","modified_gmt":"2026-03-13T13:43:15","slug":"essight-bios-es502-wins-fda-phase-i-approval-first-tcrxcd3-bispecific-targeting-ras-g12v-mutations-enters-clinic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59410","title":{"rendered":"Essight Bio&#8217;s ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic"},"content":{"rendered":"\n<p><strong>Shanghai Essight Biotechnology Co., Ltd.<\/strong> announced that <strong>ES502 Injection<\/strong> has received <strong>FDA approval<\/strong> to proceed with a <strong>Phase I clinical trial<\/strong> for patients with <strong>advanced solid tumors harboring RAS G12V mutations<\/strong> (KRAS\/NRAS\/HRAS). ES502 becomes the <strong>world&#8217;s first TCR\u00d7CD3 bispecific T\u2011cell engager (TCE)<\/strong> targeting the RAS G12V neoantigen to enter clinical development, with potential to address <strong>30\u201370% of global patients<\/strong> carrying this prevalent oncogenic driver mutation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>IND clearance for Phase I<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ES502 Injection<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Shanghai Essight Biotechnology Co., Ltd.<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced solid tumors with RAS G12V (KRAS\/NRAS\/HRAS) mutations<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>World&#8217;s first TCR\u00d7CD3 bispecific targeting RAS G12V to enter clinic<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>12\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-mechanism\">Product Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>ES502 Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Format<\/strong><\/td><td>Next\u2011generation <strong>TCR\u00d7CD3 bispecific T\u2011cell engager (TCE)<\/strong><\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>pHLA complex (RAS G12V neoantigen + HLA)<\/td><\/tr><tr><td><strong>CD3 Engagement<\/strong><\/td><td>T\u2011cell recruitment via CD3 binding<\/td><\/tr><tr><td><strong>Affinity Engineering<\/strong><\/td><td><strong>&gt;100\u00d7 higher affinity for pHLA vs. CD3<\/strong> \u2013 optimized for tumor\u2011specific activation with reduced systemic cytokine release<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>Independently developed by Essight Bio<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Mechanistic Differentiation:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Targeting:<\/strong> High\u2011specificity pHLA binding distinguishes mutant RAS from wild\u2011type<\/li>\n\n\n\n<li><strong>Conditional T\u2011Cell Activation:<\/strong> Affinity differential ensures T\u2011cell engagement occurs predominantly in tumor microenvironment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>ES502 Performance<\/th><\/tr><\/thead><tbody><tr><td><strong>Anti\u2011Tumor Activity<\/strong><\/td><td>Significant efficacy across multiple RAS G12V\u2011positive tumor models<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Excellent tissue\/organ tolerance; minimal off\u2011target toxicity<\/td><\/tr><tr><td><strong>Pharmacokinetics<\/strong><\/td><td>Favorable PK characteristics supporting dosing optimization<\/td><\/tr><tr><td><strong>Addressable Population<\/strong><\/td><td><strong>30\u201370% of RAS G12V mutation carriers globally<\/strong> (pan\u2011tumor indication potential)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-impact\">Market Context &amp; Strategic Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>RAS Mutation Prevalence<\/strong><\/td><td>RAS G12V present in <strong>~15% of solid tumors<\/strong> (pancreatic, colorectal, lung); represents <strong>largest undruggable oncogene class<\/strong> post\u2011KRAS G12C inhibitor approvals<\/td><\/tr><tr><td><strong>TCE Market Growth<\/strong><\/td><td>Global bispecific T\u2011cell engager market projected <strong>$8+ billion by 2030<\/strong>; oncology pipeline increasingly targets intracellular neoantigens<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>First\u2011mover advantage vs. TCR\u2011T cell therapies (Adaptimmune, Immatics) and other TCR bispecifics in RAS space<\/td><\/tr><tr><td><strong>Clinical Strategy<\/strong><\/td><td>Pan\u2011tumor basket trial design enables rapid expansion across KRAS\/NRAS\/HRAS G12V indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Development Pathway:<\/strong> Phase I dose\u2011escalation in solid tumors; potential for <strong>FDA Breakthrough Therapy designation<\/strong> given unmet need in RAS\u2011mutant cancers<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> Peak sales <strong>$1\u20132 billion globally<\/strong> if approved, assuming broad RAS G12V label and competitive efficacy vs. emerging KRAS inhibitors<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, patient enrollment, and therapeutic potential for ES502. Actual results may differ due to dose\u2011limiting toxicities, mutation\u2011specific HLA restriction limitations, and competitive dynamics in the RAS\u2011targeted oncology space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":59411,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,3217,25,2790],"class_list":["post-59410","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-dessight-biomedical","tag-potential-first-in-class","tag-t-cell-engager"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Essight Bio&#039;s ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed with a Phase I clinical trial for patients with advanced solid tumors harboring RAS G12V mutations (KRAS\/NRAS\/HRAS). ES502 becomes the world&#039;s first TCR\u00d7CD3 bispecific T\u2011cell engager (TCE) targeting the RAS G12V neoantigen to enter clinical development, with potential to address 30\u201370% of global patients carrying this prevalent oncogenic driver mutation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59410\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Essight Bio&#039;s ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic\" \/>\n<meta property=\"og:description\" content=\"Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed with a Phase I clinical trial for patients with advanced solid tumors harboring RAS G12V mutations (KRAS\/NRAS\/HRAS). ES502 becomes the world&#039;s first TCR\u00d7CD3 bispecific T\u2011cell engager (TCE) targeting the RAS G12V neoantigen to enter clinical development, with potential to address 30\u201370% of global patients carrying this prevalent oncogenic driver mutation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59410\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-13T13:43:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-13T13:43:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1306.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Essight Bio&#8217;s ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic\",\"datePublished\":\"2026-03-13T13:43:14+00:00\",\"dateModified\":\"2026-03-13T13:43:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410\"},\"wordCount\":460,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1306.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Dessight Biomedical\",\"Potential first-in-class\",\"T cell engager\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59410#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59410\",\"name\":\"Essight Bio's ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1306.webp\",\"datePublished\":\"2026-03-13T13:43:14+00:00\",\"dateModified\":\"2026-03-13T13:43:15+00:00\",\"description\":\"Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed with a Phase I clinical trial for patients with advanced solid tumors harboring RAS G12V mutations (KRAS\\\/NRAS\\\/HRAS). ES502 becomes the world's first TCR\u00d7CD3 bispecific T\u2011cell engager (TCE) targeting the RAS G12V neoantigen to enter clinical development, with potential to address 30\u201370% of global patients carrying this prevalent oncogenic driver mutation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59410\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1306.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/1306.webp\",\"width\":1080,\"height\":608,\"caption\":\"Essight Bio's ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59410#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Essight Bio&#8217;s ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Essight Bio's ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed with a Phase I clinical trial for patients with advanced solid tumors harboring RAS G12V mutations (KRAS\/NRAS\/HRAS). ES502 becomes the world's first TCR\u00d7CD3 bispecific T\u2011cell engager (TCE) targeting the RAS G12V neoantigen to enter clinical development, with potential to address 30\u201370% of global patients carrying this prevalent oncogenic driver mutation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59410","og_locale":"en_US","og_type":"article","og_title":"Essight Bio's ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic","og_description":"Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed with a Phase I clinical trial for patients with advanced solid tumors harboring RAS G12V mutations (KRAS\/NRAS\/HRAS). ES502 becomes the world's first TCR\u00d7CD3 bispecific T\u2011cell engager (TCE) targeting the RAS G12V neoantigen to enter clinical development, with potential to address 30\u201370% of global patients carrying this prevalent oncogenic driver mutation.","og_url":"https:\/\/flcube.com\/?p=59410","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-13T13:43:14+00:00","article_modified_time":"2026-03-13T13:43:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1306.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59410#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59410"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Essight Bio&#8217;s ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic","datePublished":"2026-03-13T13:43:14+00:00","dateModified":"2026-03-13T13:43:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59410"},"wordCount":460,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59410#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1306.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Dessight Biomedical","Potential first-in-class","T cell engager"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59410#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59410","url":"https:\/\/flcube.com\/?p=59410","name":"Essight Bio's ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59410#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59410#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1306.webp","datePublished":"2026-03-13T13:43:14+00:00","dateModified":"2026-03-13T13:43:15+00:00","description":"Shanghai Essight Biotechnology Co., Ltd. announced that ES502 Injection has received FDA approval to proceed with a Phase I clinical trial for patients with advanced solid tumors harboring RAS G12V mutations (KRAS\/NRAS\/HRAS). ES502 becomes the world's first TCR\u00d7CD3 bispecific T\u2011cell engager (TCE) targeting the RAS G12V neoantigen to enter clinical development, with potential to address 30\u201370% of global patients carrying this prevalent oncogenic driver mutation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59410#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59410"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59410#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1306.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1306.webp","width":1080,"height":608,"caption":"Essight Bio's ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59410#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Essight Bio&#8217;s ES502 Wins FDA Phase I Approval \u2013 First TCR\u00d7CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/1306.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59410"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59410\/revisions"}],"predecessor-version":[{"id":59412,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59410\/revisions\/59412"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59411"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}